Nektar therapeutics (NKTR)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10Sep'10Jun'10Mar'10
Cash flows from operating activities:
Net loss

-459,686

-440,667

-425,441

-422,776

657,473

681,313

745,699

902,713

-128,618

-96,692

-105,065

-209,160

-197,892

-153,524

-165,462

-130,441

-134,495

-81,177

-72,723

6,085

26,105

-53,916

-55,892

-143,040

-153,151

-162,013

-167,280

-194,284

-185,821

-171,855

-156,424

-136,945

-139,041

-133,978

-119,063

-103,706

-67,842

-37,938

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash royalty revenue related to sale of future royalties

38,000

36,300

36,600

34,600

34,580

33,300

33,433

33,199

30,757

30,500

29,184

28,809

30,286

30,158

29,647

28,006

24,631

22,058

19,936

20,029

20,126

21,937

26,064

24,444

23,435

22,055

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense on liability related to sale of future royalties

25,900

25,000

24,300

23,200

22,281

21,200

20,165

19,836

19,367

18,900

18,318

18,749

19,219

19,712

20,120

20,444

20,614

20,619

20,591

20,569

20,551

20,888

21,390

21,802

22,153

22,309

22,060

21,930

21,815

18,057

0

0

0

-

-

-

-

-

-

-

-

Stock-based compensation

99,646

99,795

98,993

97,400

93,537

88,101

75,392

60,940

48,380

36,615

32,175

29,506

27,671

25,850

23,963

22,559

20,855

19,669

18,869

18,229

17,833

17,017

17,190

17,632

17,824

17,708

17,349

16,765

16,210

16,199

16,399

17,238

18,317

18,885

19,184

18,976

18,457

17,399

0

0

0

Depreciation and amortization

14,581

13,156

12,653

11,887

11,406

10,870

10,459

11,569

13,249

14,741

15,930

16,004

15,669

15,351

15,248

14,656

13,597

12,855

12,303

12,241

12,636

12,927

13,126

13,513

13,911

14,275

14,580

14,837

14,626

14,508

14,337

14,254

14,605

14,951

15,476

15,866

16,258

16,551

0

0

0

Impairment of advance payments to contract manufacturers and equipment for terminated program

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Impairment of long-lived assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Accretion of premiums (discounts), net and other non-cash transactions

9,500

11,394

13,237

14,787

13,765

10,952

7,647

3,783

520

881

1,365

2,014

2,299

2,185

3,107

3,004

2,044

2,365

2,321

2,046

2,275

560

-645

-1,370

-1,302

-664

-2,211

-1,991

-2,364

-2,520

-2,967

-1,427

-1,345

-1,359

593

-613

-272

-198

0

0

0

Changes in operating assets and liabilities:
Accounts receivable

-863

-6,411

7,318

34

25,337

25,505

17,879

20,457

3,298

-10,664

-10,935

-23,663

-38,112

-4,269

11,283

24,097

36,792

16,340

-43,108

633

1,030

1,378

41,517

-2,994

-1,792

-3,576

646

-5,320

-7,156

867

-33,379

2,901

8,643

-20,164

31,737

-986

-5,549

20,301

0

0

0

Inventory

2,542

1,284

424

1,304

1,103

655

-358

876

-2,341

-383

2,900

746

1,766

-237

402

138

-1,261

-1,606

-1,343

-3,987

-361

-500

-3,381

-6,368

-5,509

-4,817

-1,678

5,764

4,273

5,613

12,876

4,918

2,396

5,390

-7,582

20

3,009

795

0

0

0

Operating leases, net

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other assets

1,952

-1,190

-8,562

1,552

29,296

31,652

24,851

21,362

5,081

4,800

8,389

2,669

2,472

312

-1,373

-3,622

-660

825

130

3,842

-233

3,294

-285

-1,653

-1,861

-6,423

-2,255

-3,363

-5,570

-6,031

3,424

1,900

6,763

12,267

-2,326

1,478

-261

-577

0

0

0

Accounts payable

10,498

12,967

14,469

-1,340

-365

971

-1,044

4,644

4,449

2,074

1,448

3,722

4,669

518

4,912

-385

-2,687

-412

-3,214

-4,551

2,008

-6,359

1,832

1,750

-1,282

6,199

976

2,429

2,523

-122

415

-155

-1,779

-3,384

-1,681

-1,058

-369

4,274

0

0

0

Accrued compensation

3,016

1,530

-4,821

730

3,241

1,674

8,834

4,634

3,667

-10,017

3,355

1,883

1,419

12,282

2,928

1,639

688

249

-948

-562

-71

-8,505

-157

299

475

5,481

1,223

568

765

-4,034

927

1,084

507

3,555

1,208

1,527

1,976

-800

0

0

0

Accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

4,701

4,584

-729

1,495

-5,690

-1,167

146

1,013

3,831

3,042

2,290

1,683

0

0

0

Accrued clinical trial expenses

-

-

-

-

-

-

-

-

-

-

0

0

-3,153

-

-156

4,524

1,849

512

1,459

-4,262

-4,979

-9,197

-5,596

-3,727

-10,306

-595

2,039

4,328

11,306

5,547

-412

-1,225

-923

-191

-1,963

-1,153

-1,070

-2,023

0

0

0

Other accrued expenses

10,758

3,816

11,363

28,038

17,895

27,947

28,909

20,306

16,305

7,277

2,514

-514

-449

-71

-841

-1,306

-1,913

-2,278

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-14,871

-16,565

-13,865

-15,797

-15,857

-15,331

-54,677

-30,631

-41,566

-28,269

10,527

-13,798

-969

-17,615

-18,363

-20,800

-26,550

-17,530

-17,976

-16,734

3,286

-4,664

3,995

-1,945

-21,066

-12,399

-20,868

-13,277

-9,900

-9,384

-8,626

-8,892

-11,735

-17,516

23,762

546

-23,012

-47,025

0

0

0

Interest payable

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-2,773

977

-2,719

0

0

0

-

-

-

0

-166

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

Other liabilities

136

533

10,373

7,178

3,164

3,545

-10,870

-10,860

-11,874

-14,928

15,461

10,347

4,377

8,622

-6,615

-9,465

-5,511

3,032

-2,581

4,528

-2,327

-13,801

6,623

3,830

11,799

9,164

-1,331

2,321

-1,111

3,275

1,519

-554

1,157

-943

-879

-176

-489

-247

0

0

0

Net cash used in operating activities

-325,861

-328,681

-321,008

-323,779

689,785

718,214

755,363

919,851

-98,314

-80,414

-52,424

-172,861

-127,942

-117,024

-139,722

-126,392

-160,043

-73,083

-22,601

-54,574

-16,404

-142,006

-63,748

-37,454

-62,706

-38,527

-139,534

-146,995

-133,249

-129,756

-124,594

-119,293

-133,490

-113,742

-51,121

-51,413

-36,578

-55,871

0

0

0

Cash flows from investing activities:
Purchases of investments

1,253,194

1,380,865

0

0

0

-

-

-

-

404,425

506,126

382,988

379,064

334,659

237,710

245,946

304,628

297,608

299,961

255,223

211,022

297,251

327,659

325,164

322,393

268,068

178,622

153,652

118,975

164,662

194,451

306,100

424,671

695,371

755,491

734,528

700,568

443,122

0

0

0

Maturities of investments

1,691,522

1,614,036

1,546,201

1,392,323

1,215,974

890,957

554,289

332,964

326,922

347,743

313,345

293,877

242,358

253,682

272,689

223,285

222,866

226,923

231,852

240,219

264,457

247,995

216,996

237,481

275,815

319,181

379,130

328,598

256,261

307,887

295,010

405,856

421,781

383,052

405,717

391,519

476,974

475,813

0

0

0

Sales of investments

-

-

-

-

-

12,000

40,677

40,677

40,640

37,500

8,823

13,792

13,792

4,969

23,735

37,329

37,329

42,544

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

210,089

223,849

187,760

68,650

15,479

0

0

0

Purchases of property, plant and equipment

21,537

26,285

31,301

27,800

18,902

14,239

7,945

7,062

6,572

9,676

9,934

9,502

8,802

6,392

6,214

9,845

11,815

11,195

12,608

9,368

6,511

9,976

8,799

8,489

8,299

4,091

6,221

8,205

9,383

10,583

7,172

6,049

7,473

9,722

17,591

29,506

31,249

31,457

0

0

0

Net cash provided by (used in) investing activities

416,791

206,886

158,945

-520,579

-1,440,284

-1,379,936

-1,444,498

-903,916

32,471

-28,809

-193,892

-84,821

-131,716

-82,400

52,500

29,823

-31,248

-14,336

-31,939

2,504

73,800

-37,571

-94,914

-93,285

-51,990

49,909

194,287

147,119

108,281

113,020

65,194

123,318

138,358

-111,952

-143,516

-184,755

-186,193

16,713

0

0

0

Cash flows from financing activities:
Issuance of common stock to Bristol-Myers Squibb (Note 10)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

116,536

0

0

0

-

-

-

-

-

-

-

-

219,783

0

0

0

-

0

0

0

Repayment of proceeds from sale of future royalties

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-7,000

-7,000

-7,000

-7,000

-3,000

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

(Repayment of) proceeds from sale of future royalties, net of $4.4 million of transaction costs in 2012

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

Proceeds from shares issued under equity compensation plans

29,538

23,355

21,117

18,727

32,277

61,735

86,314

92,714

82,082

59,522

34,521

32,660

25,983

20,287

34,733

34,053

36,619

32,208

46,332

46,821

43,595

46,984

19,123

13,548

12,064

8,208

6,193

5,401

4,856

4,117

0

0

0

-

-

-

-

-

-

-

-

Payment of capital lease obligations

-

-

-

-

-

-

-

-

-

5,131

2,728

3,797

4,835

5,945

6,765

6,220

5,812

5,187

4,756

4,370

3,809

3,536

3,369

3,176

3,125

2,992

2,865

2,752

2,563

2,437

2,320

2,195

2,085

1,978

1,668

1,559

1,456

1,356

0

0

0

Net cash provided by financing activities

29,538

23,355

21,117

18,727

822,508

851,966

873,573

879,183

77,564

54,391

221,069

218,139

210,424

203,618

131,730

131,595

134,569

130,783

41,576

42,386

39,703

152,984

125,290

119,973

118,558

2,216

262

-94,819

-95,175

26,801

26,285

119,495

120,338

222,335

224,153

224,733

224,617

7,535

0

0

0

Effect of foreign exchange rates on cash and cash equivalents

-185

-102

-91

-70

-62

-101

-144

-142

-396

-46

-81

16

165

-124

-32

-225

-181

-159

-225

-140

-90

-109

-31

33

50

32

58

-27

189

60

0

0

0

-

-

-

67

-219

0

0

0

Net increase (decrease) in cash and cash equivalents

120,283

-98,542

-141,037

-825,701

71,947

190,143

184,294

894,976

11,325

-54,878

-25,328

-39,527

-49,069

4,070

44,476

34,801

-56,903

43,205

-13,189

-9,824

97,009

-26,702

-33,403

-10,733

3,912

13,630

55,073

-94,722

-119,954

10,125

-32,670

124,528

126,000

-2,443

30,102

-11,618

1,913

-31,842

0

0

0

Supplemental disclosures of cash flow information:
Cash paid for interest

19,345

19,199

18,999

19,131

19,324

19,471

19,828

19,901

20,001

20,116

20,065

20,151

20,412

20,589

19,643

22,353

17,614

20,225

17,053

17,143

17,339

17,445

16,980

17,142

17,301

17,590

17,707

13,511

13,671

9,620

0

0

0

-

-

-

-

-

-

-

-

Operating lease right-of-use asset recognized in exchange for lease liabilities

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-